FORA vs. POET, WILC, LIFW, HLTH, MGRM, PMVP, CMRX, CVM, BTAI, and ETON
Should you be buying Forian stock or one of its competitors? The main competitors of Forian include POET Technologies (POET), G. Willi-Food International (WILC), MSP Recovery (LIFW), Cue Health (HLTH), Monogram Orthopaedics (MGRM), PMV Pharmaceuticals (PMVP), Chimerix (CMRX), CEL-SCI (CVM), BioXcel Therapeutics (BTAI), and Eton Pharmaceuticals (ETON).
Forian (NASDAQ:FORA) and POET Technologies (NASDAQ:POET) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
In the previous week, POET Technologies had 2 more articles in the media than Forian. MarketBeat recorded 4 mentions for POET Technologies and 2 mentions for Forian. Forian's average media sentiment score of 0.42 beat POET Technologies' score of 0.12 indicating that Forian is being referred to more favorably in the media.
Forian has higher revenue and earnings than POET Technologies. POET Technologies is trading at a lower price-to-earnings ratio than Forian, indicating that it is currently the more affordable of the two stocks.
19.3% of Forian shares are owned by institutional investors. Comparatively, 2.0% of POET Technologies shares are owned by institutional investors. 31.3% of Forian shares are owned by company insiders. Comparatively, 0.5% of POET Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Forian received 6 more outperform votes than POET Technologies when rated by MarketBeat users. Likewise, 90.00% of users gave Forian an outperform vote while only 60.00% of users gave POET Technologies an outperform vote.
Forian presently has a consensus target price of $7.67, suggesting a potential upside of 194.87%. POET Technologies has a consensus target price of $7.50, suggesting a potential upside of 228.95%. Given POET Technologies' higher possible upside, analysts plainly believe POET Technologies is more favorable than Forian.
Forian's return on equity of 0.00% beat POET Technologies' return on equity.
Forian has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, POET Technologies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
Summary
Forian beats POET Technologies on 13 of the 16 factors compared between the two stocks.
Get Forian News Delivered to You Automatically
Sign up to receive the latest news and ratings for FORA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FORA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
